utrbpa

Property	Value
?:abstract	A population of more than six million people worldwide at high risk of Alzheimer\'s disease (AD) are those with Down Syndrome (DS, caused by trisomy 21 (T21)), 70% of whom develop dementia during lifetime, caused by an extra copy of ß-amyloid-(Aß)-precursor-protein gene. We report AD-like pathology in cerebral organoids grown in vitro from non-invasively sampled strands of hair from 71% of DS donors. The pathology consisted of extracellular diffuse and fibrillar Aß deposits, hyperphosphorylated/pathologically conformed Tau, and premature neuronal loss. Presence/absence of AD-like pathology was donor-specific (reproducible between individual organoids/iPSC lines/experiments). Pathology could be triggered in pathology-negative T21 organoids by CRISPR/Cas9-mediated elimination of the third copy of chromosome 21 gene BACE2, but prevented by combined chemical ß and Î³-secretase inhibition. We found that T21 organoids secrete increased proportions of Aß-preventing (Aß1-19) and Aß-degradation products (Aß1-20 and Aß1-34). We show these profiles mirror in cerebrospinal fluid of people with DS. We demonstrate that this protective mechanism is mediated by BACE2-trisomy and cross-inhibited by clinically trialled BACE1 inhibitors. Combined, our data prove the physiological role of BACE2 as a dose-sensitive AD-suppressor gene, potentially explaining the dementia delay in ~30% of people with DS. We also show that DS cerebral organoids could be explored as pre-morbid AD-risk population detector and a system for hypothesis-free drug screens as well as identification of natural suppressor genes for neurodegenerative diseases.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/20utrbpa_hasAnnotation_C0017337> <https://research.tib.eu/covid-19/entity/20utrbpa_hasAnnotation_C0017372> <https://research.tib.eu/covid-19/entity/20utrbpa_hasAnnotation_C0020517> <https://research.tib.eu/covid-19/entity/20utrbpa_hasAnnotation_C0041107> <https://research.tib.eu/covid-19/entity/20utrbpa_hasAnnotation_C0220806> <https://research.tib.eu/covid-19/entity/20utrbpa_hasAnnotation_C0497327> <https://research.tib.eu/covid-19/entity/20utrbpa_hasAnnotation_C1412727> <https://research.tib.eu/covid-19/entity/20utrbpa_hasAnnotation_C1412728> <https://research.tib.eu/covid-19/entity/20utrbpa_hasAnnotation_C1825092> <https://research.tib.eu/covid-19/entity/20utrbpa_hasAnnotation_C3658200>
?:creator	<https://research.tib.eu/covid-19/entity/Alic%2C_Ivan%3B_Goh%2C_Pollyanna_A%3B_Murray%2C_Aoife%3B_Portelius%2C_Erik%3B_Gkanatsiou%2C_Eleni%3B_Gough%2C_Gillian%3B_Mok%2C_Kin_Y%3B_Koschut%2C_David%3B_Brunmeir%2C_Reinhard%3B_Yeap%2C_Yee_Jie%3B_O039%2C%3B_Brien%2C_Niamh_L%3B_Groet%2C_J%C3%BCrgen%3B_Shao%2C_Xiaowei%3B_Havlicek%2C_Steven%3B_Dunn%2C_N_Ray%3B_Kvartsberg%2C_Hlin%3B_Brinkmalm%2C_Gunnar%3B_Hithersay%2C_Rosalyn%3B_Startin%2C_Carla%3B_Hamburg%2C_Sarah%3B_Phillips%2C_Margaret%3B_Pervushin%2C_Konstantin%3B_Turmaine%2C_Mark%3B_Wallon%2C_David%3B_Rovelet-Lecrux%2C_Anne%3B_Soininen%2C_Hilkka%3B_Volpi%2C_Emanuela%3B_Martin%2C_Joanne_E%3B_Foo%2C_Jia_Nee%3B_Becker%2C_David_L%3B_Rostagno%2C_Agueda%3B_Ghiso%2C_Jorge%3B_Krsnik%2C_Zeljka%3B_Simic%2C_Goran%3B_Kostovic%2C_Ivica%3B_Mitrecic%2C_Dinko%3B_Francis%2C_Paul_T%3B_Blennow%2C_Kaj%3B_Strydom%2C_Andre%3B_Hardy%2C_John%3B_Zetterberg%2C_Henrik%3B_Nizetic%2C_Dean>
?:journal	Mol._psychiatry
?:license	unk
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
?:source	WHO
?:title	Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:who_covidence_id	#32647257
?:year	2020

Property

Value

?:abstract

A population of more than six million people worldwide at high risk of Alzheimer\'s disease (AD) are those with Down Syndrome (DS, caused by trisomy 21 (T21)), 70% of whom develop dementia during lifetime, caused by an extra copy of ß-amyloid-(Aß)-precursor-protein gene. We report AD-like pathology in cerebral organoids grown in vitro from non-invasively sampled strands of hair from 71% of DS donors. The pathology consisted of extracellular diffuse and fibrillar Aß deposits, hyperphosphorylated/pathologically conformed Tau, and premature neuronal loss. Presence/absence of AD-like pathology was donor-specific (reproducible between individual organoids/iPSC lines/experiments). Pathology could be triggered in pathology-negative T21 organoids by CRISPR/Cas9-mediated elimination of the third copy of chromosome 21 gene BACE2, but prevented by combined chemical ß and Î³-secretase inhibition. We found that T21 organoids secrete increased proportions of Aß-preventing (Aß1-19) and Aß-degradation products (Aß1-20 and Aß1-34). We show these profiles mirror in cerebrospinal fluid of people with DS. We demonstrate that this protective mechanism is mediated by BACE2-trisomy and cross-inhibited by clinically trialled BACE1 inhibitors. Combined, our data prove the physiological role of BACE2 as a dose-sensitive AD-suppressor gene, potentially explaining the dementia delay in ~30% of people with DS. We also show that DS cerebral organoids could be explored as pre-morbid AD-risk population detector and a system for hypothesis-free drug screens as well as identification of natural suppressor genes for neurodegenerative diseases.

is ?:annotates of